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Abstract
To provide a single molecular assay that could be used to easily stage Multiple Myeloma patients at diagnosis, we
investigated the association between the simultaneous expression of 7 Multiple Myeloma-associated Cancer/Testis
Antigens and biochemical parameters that are currently used for disease staging. We analysed the mRNA
expression of MAGEC1, MAGEA3/A6, BAGE2, PRAME, NYESO1, SSX2 and PAGE by qualitative reverse
transcription PCR using RNA extracted from diagnostic bone marrow samples from 39 patients covering the Multiple
Myeloma disease continuum and compared this to levels of key biochemical parameters at diagnosis. We found that
the Cancer/Testis Antigen panel was expressed in a specific order that was specifically associated with the severity
of disease. This allowed the Cancer/Testis Antigens expression profile to successfully place the patient clearly into
either stage I or stage III of the disease, with further sub-stratification in the stage III grouping. In addition, we
putatively identified MAGEC1 expression as a confirmatory diagnostic marker for symptomatic Multiple Myeloma
and clearly associated BAGE2 expression exclusively with stage III disease. We also demonstrated the novel finding
of PAGE expression in Multiple Myeloma, with an association with more advanced disease. We suggest that this
particular molecular Cancer/Testis Antigen panel can be used at diagnosis as a single test to clearly stage patients.
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Introduction
Multiple Myeloma (MM) is a hematological malignancy that is
characterized by the accumulation of monoclonal malignant plasma
cells in the bone marrow (BM), and elevated serum or urine
monoclonal paraproteins. Severe clinical manifestations occur due to
the accumulation of plasma cells in the BM, which results in anemia,
immunodeficiency and lytic bone lesions, as well as overproduction of
paraproteins. Complete remission is easily induced in patients with
high dose chemotherapy and stem cell rescue protocols, but relapse
and death are extremely common and the disease is currently
incurable [1,2].
There are a number of factors that influence a MM patient’s
prognosis and response to therapy [3-7] including: disease stage, renal
impairment, tumor burden, severity of anaemia, proliferation index of
the plasma cells (PCPI) and chromosomal abnormalities. The
International Staging System (ISS), is based on levels of β2
microglobulin (B2M) and albumin, and the Durie-Salmon Staging
(DSS) index that looks at M-protein levels, the presence of bone
lesions, haemoglobin (Hb), calcium and serum creatinine levels [8,9].
While both staging systems are fairly successfully in staging disease
into 3 large categories, multiple additional tests are required to be able
to sub-classify the patients into more specific prognostic subgroups.
Not only is this process expensive, but often not possible due to the
range of laboratory expertise that is required and thus a comprehensive
patient prognostic profile is often not achieved.
The concept of a single molecular panel that can be used to both
stage and further sub-group high risk patients is thus an attractive
alternative approach. Unfortunately, the genetic background of MM is
very complex, with multiple chromosomal abnormalities occurring in
different patients.
In the search for common genetic profiles in MM, Cancer/Testis
antigens (CTAs) were investigated. These genes encode proteins that
show testis-restricted expression in normal tissue, but high expression
in many different cancer types [10-12]. The expression of these
proteins has been associated with a worse prognosis in many cancers
in addition to MM and in particular with the proliferative nature of the
tumours [13,14]. Although the full panel of CTAs has yet to be tested
in MM patients, the following CTAs have been found to be expressed
in 20-80% of cases: MAGEC1 and MAGE A3/6, SP-17, PRAME,
NYESO1, SSX family (1,2,5) and BAGE [15-19]. While commonly
expressed, the role in MM pathogenesis is unclear, with hints at a
possible cascade-like effect occurring where the expression of multiple
CTAs appears to be associated with advanced disease [17,19,20].
It is thus possible that a CTA panel maybe useful in sub-typing MM
prognostic groups. If we and others are successful in linking CTA
expression patterns with major prognostic indicators, then this assay
could easily be offered as a quick molecular service, providing vital
prognostic information to clinicians.
The aim of this study was to establish an association between CTA
expression (7 CTAs) and key disease staging/prognostic factors in
newly diagnosed MM patients, to be able to define a genetic panel that
has clinical value at diagnosis.
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Materials and Methods
Patient selection, diagnosis and disease staging
Newly diagnosed patients with untreated MM or monoclonal
gammopathy of undetermined significance (MGUS) from the
Haematology clinic, Groote Schuur Hospital (GSH) and UCT Private
Academic Hospitals (Cape Town, South Africa) were enrolled for the
study over a 24 month period. This study was approved by the Human
Research Ethics Committee University of Cape Town: HREC/REF
125/2009 and all participants gave their written informed consent to
participate. Patients with known HIV+ status and secondary
malignancies were excluded from the study. The following chemistry
and haematology parameters were collected within two weeks of the
diagnostic BM sample using standard pathological test methods
(National Health laboratory Services- GSH (NHLS/GSH)): Hb (g/dl) ,
BM aspirate plasma cell count, B2M (mg/l) , Urine Bence Jones Protein
(UBJP) (g/24 h), creatinine (µmol/l), monoclonal serum Ig levels























































*= Primers cannot distinguish between A3 and A6, as they have identical coding
regions.
# = Primers designed for this study.
$ = all primers used at 25 pmol/reaction except PRAME set-50 pmol/reaction.
Table 1: Primers used for qualitative CTA PCR analysis.
Patients were diagnosed as suffering from symptomatic MM
(SMM), asymptomatic MM (AMM) or MGUS, based on the following
criteria: 1) SMM: Clonal plasma cell population in BM or
plasmacytoma; M-protein in serum or urine; evidence of organ
damage: CRAB (WHO criteria [21])- corrected calcium ˃2.56 mmol/l,
serum creatinine ˃90 µmol/l (F) ˃110 µmol/l (M), Hb˂12 g/dl (F) ˂13
g/dl (M), and/or evidence of bone lytic lesions. 2) AMM: M-protein in
serum ˃30 g/l and/or ≥10% clonal plasma cells in BM; No evidence of
CRAB symptoms. 3) MGUS: M-protein in serum ˂30 g/l; BM plasma
cells ˂10%; no evidence of CRAB symptoms [21]. The disease stage of
the patient was calculated according to a modified DSS [8,21] (based
on the fact that our patients did not have their myeloma cell mass
assessed).
PCPI and aneuploidy
A) The PCPI was generated using a Ki-67/CD138 (Becton Dickson)
dual-labelling approach on mononuclear cells with analysis by flow
cytometry (anti-Ki67 FITC, ABCAM; anti-CD138 APC, Becton
Dickson) with a minimum of 10000 CD138 positive cells being
analysed Ki-67+/CD138+ populations of ˃20% were resulted as positive
for the proliferation marker. B) Aneuploidy DNA analysis was
performed on unfractionated BM aspirate stained with propidium
iodide (PI) [22]. The DNA content of 30 000 events in the lymphocyte
gate was then analysed using the PI histogram, with the geometric
mean value of the major G0/G1 peak being calculated (P1). Sex-
matched controls were used for the analysis of each patient to be able
to compare DNA content. A DNA index (MM PI/ control PI) of 0.95 –
1.05 was regarded as normal, hypodiploid ˂0.95, and hyperploid
˃1.05–1.75 [23]. The PI staining of lymphocytes allowed aneuploidy
subpopulations of ˃10% to be scored in patients with ˃5% plasma
cells.
CTA qualitative mRNA expression
Mononuclear cells from 2-5 ml BM aspirate were enriched using
standard ficoll density centrifugation (Histopaque-1077, Sigma, USA).
Approximately 1×107 mononuclear cells were resuspended in Total
RNA Isolation Reagent (TRIR) (ABgene, USA) and RNA extracted
according to the manufacturer’s recommendations and stored in single
use aliquots. Only samples fulfilling the following criteria were
acceptable for analysis: 260/280 ratio ˃1.7, and ˃180 ng/µl. The
expression of CTA mRNA was assessed using a 2-step RT-PCR
protocol using random hexamers for global cDNA synthesis (20 µl):
MMLV RT buffer, 1 µg random hexamers (Promega, USA), 1 mM
dNTP mix (Sigma, USA), 20 U RNAsin (Promega, USA), 100 U
MMLV (Promega, USA) and 1 µg heat–denatured RNA. The following
cDNA reaction parameters were used: 22°C/10 min, 42°C/60 min,
99°C/5 min.
The expression of 7 CTAs and the reference gene β-actin was
simultaneously assessed using 7 PCR reactions from a single patient
RT reaction. PCR primer sequences are indicated in Table 1 and all
were designed to amplify across introns. The following PCR reaction
mix was used (25 µl): Green GoTaq buffer, 1.5 U GoTaq HotStart
(Promega, USA), 0.8 mM dNTP mix (Sigma, USA), 1.5 mM MgCl2
and 2 µl cDNA and amplified under the following conditions: 95°C/5
min, 35 cycles of 94°C/30 sec, 55°C/40 sec and 72°C/90 sec with a final
8 min soak at 72°C. Amplicons were simultaneously separated on 3%
TAE/agarose gels and visualized with EtBr staining. CTA expression
results were not recorded if the β-actin amplification was inadequate.
Samples were analyzed in duplicate.
Results
Development of the qualitative CTA expression assay
The molecular assay was developed to simultaneously assess the
expression of 7 CTA genes from a single RNA sample: PRAME,
MAGEC1, MAGEA3, PAGE, BAGE2, NYESO1, and SSX2, allowing
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the relationship between the genes to be investigated (as shown in
Figure 1). Several controls, including human testis RNA (Clontech,
USA), human tonsil RNA (plasma cell progenitors [27]; Clontech,
USA), as well as 5 donors PB and BM samples (including CD34+
purified cells) were used to confirm the integrity of the results and link
the CTA expression directly to diseased cells and human testis tissue
only. A previous study, using flow cytometry to detect MAGEC1 in PB
and BM samples, showed that malignant CTA expression in MM is
associated with early stem cells (CD34+) and early pro-B to pre-B cells
(CD34+/−/CD19+), with only the proliferating compartment of
plasma cells expressing the malignant marker [28]. Amplicon
sequencing confirmed detection of the correct transcript with this
assay using both human testis RNA and MM patient RNA. The assay
demonstrated a detection sensitivity of approximately 1% (1:100
human testis/donor PB RNA).
Figure 1: Qualitative RT-PCR assessment of selected CTA
expression in Human testis. Lane1-low molecular weight DNA
marker (NEB) (bp), Lane 2 – BAGE2 amplicon (267bp), Lane 3 -
NY-ESO-1 (330bp), Lane 4 - SSX2 (434bp) and PAGE (232bp),
Lane 5 – PRAME (520bp) Lane 6 - β-Actin (540bp), Lane 7-
MAGEA3/A6 (175bp (larger band: DNA amplification), Lane 8 -
MAGEC1 (380bp), Lane 9 – extraction blank amplified with β-actin
primers.
Links between the number of CTAs expressed and disease
characteristics
The majority of the patients diagnosed during the research period
were MM patients referred from local primary health clinics (Figure
2), and consequently most were classified as stage III according to
classical DSS methods. We were hoping to be able to provide an
objective tool for clinicians to be able to sub-stratify these stage III
patients for more effective management with this study. In total, 39
patients were included, representing the continuum from MGUS to
SMM: 5 MGUS, 8 stage I, 5 stage II and 21 stage III MM patients. The
distribution of Ig subtype in the patient population correlated well with
previous studies [29], with a slight male gender bias of 1.2:1 for this
cohort also being typical for MM reported cases internationally [30].
The considerably earlier average age of only 59.4 yrs (33-84 yrs range)
compared to 69 was however unexpected [31]. The expression of CTAs,
disease classification, staging and CRAB symptoms at diagnosis for
each patient is summarized in Figure 3. All 30 of the SMM patients,
expressed at least one of the CTA panel members, namely MAGEC1.
There was a strong association (R2 = 0.74) between the number of
CTAs expressed and the stage of the disease as characterized by the
DSS method, with the expression of 1-2 CTAs only observed in stage I
and II disease, while all stage III patients expressed 3-6 genes at
diagnosis. This association was further strengthened by the increase in
the number of CTAs expressed by two AMM patients who progressed
to MM within 12 months, both showing no CTA expression at initial
diagnosis and 3 (stage II) and 6 (stage III) genes, respectively at follow
up. With regards to disease subtype, light chain MM disease is known
to offer a worse prognosis [32,33], with rapid kidney failure. While we
only had 5 patients in this grouping at diagnosis, all presented with
advanced disease (stage III, 3-4 CRAB symptoms) and
correspondingly expressed 5-6 CTAs (Figure 2).
Figure 2: Patient study population at diagnosis. Pie chart showing
the disease classification of the 39 patients analyzed in the study,
according to WHO criteria [21]. The number of patients classified
in each category is indicated, as well as the % of those patients
expressing κ light chain clonality. LC: light chain disease.
Due to the clear association between disease progression and the
number of CTAs expressed, the biological parameters used for staging
and defining the CRAB scoring (a direct indicator of disease
progression) in MM patients were further analyzed, showing that the
increasing number of CTA mRNAs detected showed good correlation
with the severity of the CRAB defining features (Figure 4A). Figure 4A
shows the linear correlation between the severity of the anemia, the
increase in B2M and increasing leached calcium levels with the
number of CTAs expressed. Clinically high creatinine was only
associated with the expression of 5-6 CTA’s (all stage III disease),
indicating a possible subgroup. In addition, the majority of patients
presenting with multiple lytic lesions (86%), again a poor prognostic
indicator, grouped together, expressing 4-6 CTAs (Figure 3). Serum M-
protein and UBJP are an indication of tumor burden and thus stage of
disease and are regularly used to monitor patient therapy progress.
Figure 4B shows the relationship between these protein levels and the
number of CTAs expressed. The serum M-protein levels rapidly
increased as the CTA number increased from 0-3 and then remained at
a high level for patients expressing 4-6 CTAs. For patients in this group
(4-6 CTAs), this correlated as expected with a sharp spike in the UBJP
levels (>1), which is associated with renal damage as the IgM levels
rise. Another indicator of tumor burden is the plasma cell load in the
BM. However, Figure 4B shows that no clear relationship was observed
between the percentage of plasma cells in the BM aspirate and the
number of CTA mRNAs detected. The quantification of plasma cells in
the aspirate or BM trephine is however highly dependent upon the area
sampled and can be inaccurate. The characteristics of the plasma cells,
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including their presence in the PB, proliferation status and their
abnormal nuclear staining are additional independent prognostic
factors that can be considered. Circulating plasma cells, which is
indicative of more aggressive disease [33,34] were only observed in 9
patients, 78% of whom presented with stage III disease. However, this
subgrouping showed no specific CTA expression pattern (in number or
specific gene). There was also no association of specific CTA expression
to plasma cell proliferation (PCPI) (results not shown) or the
aneuploidy status of the patient’s plasma cell population, with all
patients analyzed having the hyperdiploid status.
Expression profiles of specific CTAs in MM
Two specific CTAs, namely MAGEC1 and BAGE, were found to be
the most informative. Firstly, MAGEC1 expression was strongly linked
to a diagnosis of all SMM patients while no MGUS or AMM patients
showed detectable transcript at diagnosis (Figure 3). Secondly, BAGE2
expression was specifically linked with stage III disease and
significantly associated with poor hematological parameters. This was
demonstrated by the mean values for this patient group all falling
within the WHO classification for all of the CRAB symptoms [21],











UBJP (g/24hrs) 2.45 (0.50-6.83) 0.15 (0.00-0.96) 0.0009
Hb(g/dl) 8.6* (6.8-9.7) 11.09 (7.2-14.1) 0.0016
B2M (mg/l) 21.6 (9.0-34.7) 6.0 (2.3-10.5) 0.0028
Corrected Calcium
(mmol/l) 2.57
* (2.12-3.41) 2.33 (2.19-2.79) 0.0222
Creatinine (µmol/l) 257* (58-1250) 75 (55-116) 0.0267
Serum M-protein (g/l) 44.3 35.6 0.2543
Albumin (g/l) 32 34 0.6976
LDH (U/l) 370 373 0.9503
* = indicative of WHO and IWMG CRAB symptoms
# = statistical difference between groups expressing/not expressing BAGE2.
Values ˂0.05 regarded as significant and highlighted in purple.
Table 2: Biochemical characteristics of MM patients expressing
BAGE2.
Several biological parameters showed a significant difference
between the BAGE2+ and BAGE2- groups (p˃0.05), with the levels of
UBJP, B2M and Hb showing the highest significant difference
(p˃0.005) (Table 2). Interestingly, 88% (7/8) of patients with high PB
calcium levels belonged to this BAGE2+ cohort, which not surprisingly
also included 92% of the 13 patients with confirmed multiple lytic
lesions. The patients in the BAGE2+ cohort also exhibited the highest
indicators for renal damage in the total MM cohort, with creatinine
and B2M levels as high as 1250 µmol/l and 34.7 mg/l respectively. No
significant difference was however found with regards to the
association of BAGE2 expression with lower albumin or increased
lactate dehydrogenase (LDH) levels (Table 2), both of which have been
reported to be associated with a worse prognosis [35,36].
Figure 3: Qualitative CTA expression in the patient cohort. Patient
CTA expression data is arranged according to the number of CTAs
simultaneously expressed in each RNA BM sample. Information
reading the classical MM features used for diagnosis and prognosis
are provided for each patient. For DSS data, a and b subscript refers
to the DSS subgroupings based on creatinine levels [21] and the
lack of X-ray information could not accurately determine if 2
patients were actually stage II or stage III disease (indicated with
a*), Regarding lytic lesion scoring, patients were scored as single for
lytic lesions if a single lesion/ fracture or plasmacytoma was found
at diagnosis via X-ray.
While the other CTAs in the panel did not show such clear
associations as MAGEC1 and BAGE2, the expression results still
showed potential value of which PAGE was of particular interest.
PAGE was expressed in half of the SMM patients at diagnosis and
although PAGE has not been previously investigated in MM disease,
we show that it is fairly commonly expressed in mainly more advanced
disease patients (87% classified as stage III disease). While its
expression does not as clearly define distinct groupings as BAGE2, the
PAGE+ patients do still present with significantly worse anemia (Hb
˂10 g/dl) and significantly higher UBJP and creatinine levels
indicating renal damage (Table 3) than the PAGE- patients.
MAGEA3 occurred in 79% of SMM patients and was again
associated with advanced disease [17,19] with 21/23 patients in this
cohort diagnosed with stage III MM. There was a very strong
correlation between expression of this CTA and anemia (p ˂0.0005),
with an average Hb value of 9.0 for this group. However, there was less
statistical difference between the MAGEA3 positive and negative
groups compared to BAGE2 expression for all the other haematological
parameters (all p values˃0.02).
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NYESO1 and SSX2 expression was only associated with stage III
disease, specifically with advanced renal damage (creatinine ave 442
µmol/l units and abnormal calcium ave: 2.67 mmol/l) and extensive
bone deterioration (multiple lytic lesions). The co-expression of
NYESO1 and/or SSX2 and BAGE2 did show a slight increase in the
levels of creatinine and calcium (p˂0.5) over the BAGE2 only cohort,
indicating that these CTAs may be useful in stratifying the stage III
group of patients.




Elevated creatinine (µmol/l) 0.0174 0.0267
Elevated UBJP (g/24hrs) 0.0087 0.0009
Reduced Hb (g/dl) 0.0164 0.0016
Elevated B2M (mg/l) 0.1420 0.0028
Elevated Corrected Calcium (mmol/l) 0.3956 0.0222
* = statistical difference between groups expressing/not expressing PAGE.
Values ˂0.05 regarded as significant and are highlighted in purple
# = statistical difference between groups expressing/not expressing BAGE2.
Table 3: Biochemical parameters in MM patients: Significance of
BAGE2 and PAGE expression.
Association between CTAs
Ordering the patients according to the number of CTAs expressed
(Figure 3) and the above observations of both the number and specific
CTAs being associated with more advanced disease, illustrated a
possible progressive pattern of CTA expression during the disease
pathogenesis. This hypothesis was further strengthened by the strong
association of specific CTAs to co-expression with others; for example
all patients expressing BAGE2 or PAGE co-expressed MAGEC1 and
MAGEA3, while 75% (12/16) patients expressing BAGE2 also
expressed PAGE (Figure 2).
Looking at these associations, a possible cascade-like effect appears
to be associated with disease progression (Figure 5). Interestingly 2
distinct patterns of expression were observed when 6 CTAs were
expressed in the stage III patients, namely those defined as light chain
disease, who expressed MAGEC1, PRAME, PAGE, BAGE, MAGE A3
and NYESO1 and IgG Kappa patients expressing MAGEC1, PAGE,
BAGE MAGE A3, NYESO1 and SSX2. The numbers of patients in
these groupings were too small to make any significant findings, but
this may suggest a difference in the disease pathogenesis of these sub
types.
Figure 4: Association of classical MM disease parameters with the number of CTAs expressed. Patients were grouped according to the number
of CTAs that were detected via the qualitative assay. The diagnostic values of certain biochemical parameters associated with various CRAB
features (A) or tumor burden indicators (B) were collected for these patients and the average of each grouping plotted to show the trend. The
regression line was calculated were possible (dotted line), with the R2 value shown on the graph. UBJP data is represented by a dashed line.
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Discussion
There are a number of factors at diagnosis of MM that can influence
a patient’s overall prognosis, including response to specific therapy in
MM and survival statistics. The data that needs to be accumulated at
diagnosis to establish prognosis can be exhaustive, including standard/
specialized biochemical tests, cytogenetics, specialized staining/flow
cytometry and extensive X-ray/MRI analysis [4-7]. Unfortunately, for a
variety of reasons, this plethora of data is regularily not available and a
clinician may be faced with not even being able to accurately stage the
patient, the very basic of prognostic indicators. This is particularily a
problem in our tertiary state hospital environment in South Africa
(SA), where patients are referred from a local clinic. Often important
preliminary data is not acquired or transferred to the hospital clinican
and the initiation of treatment at these facilities then prevents the
acquistion of important diagnostic biochemical parameters for
successful managment. This is then compounded by the lack of full
skeletal surveys, inability to obtain sufficient 24 hr urine samples and
specialised assays requests, as well as the difficulty in obtaining
cytogenetic data due to the non-proliferative nature and low count of
the plasma cells in the majority of the patients at diagnosis. Although
these problems are not issues in a large clinical trial setting, they are
not unique to our institution and standard MM patient care suffers as a
consequence. It is therefore imperative that a simple and quick assay is
designed to summarise as much of the data as possible, giving the
clinican an easy-to-interpret analysis of the disease stage of the patient
and possible high risk indications to help guide the clinician more
effectively. The aim of our study was to link the expression of specific
CTAs to known prognostic factors to establish a molecular panel that
could be used to simplify risk stratification. The use of large genetic
panels is useful in research environments, but more focused panels are
preferential in a diagnostic environment, where their accuracy/
reproducibility and cost can be more easily controlled and therefore
the data of more clinical relevance. Thus we chose 6 CTAs that have
previously been shown to be commonly expressed in MM patients,
namely PRAME, MAGEC1, MAGEA3, BAGE2, NYESO1, and SSX2
and looked at the simultaneous expression of these genes along with
PAGE, a CTA not yet examined in MM. Most of these CTAs have
previously been studied in isolation or as a small grouping, with
researchers trying to associate the link of gene expression to specific
prognostic indicators. Unfortunately, most of the results are
contradictory, with the exception of the expression of multiple CTAs,
which has been loosely linked with some indicators of advanced
disease [17,18,20,37-40]. Defining whether these genes are associated
with specific symptoms of the disease (comprehensive biochemical
assessment) and if expression is useful in sub-classifying different
disease stages has not yet been clarified.
Using our specific 7 CTA panel we found very good correlation
between the number of CTAs expressed and the stage of the disease, in
agreement with other studies [17,18,20,37-40]. More importantly, we
found significant correlation specifically with the severity of the
symptoms. In summary, the expression of 1-2 CTAs was only observed
in stage I and II disease, while all stage III MM patients expressed 3-6
genes at diagnosis. There was a linear correlation between the number
of CTAs expressed and the severity of the anemia, B2M levels and
calcium levels, with patients expressing 4-6 CTAs demonstrating worse
biochemical features and a link to poor prognostic indicators [6,41,42].
The increase in serum M-protein followed by detectable UBJP also
correlated with the increase in CTA expression, with high
immunoglobulin levels and thus a high disease burden being present in
patients expressing 4-6 CTAs. The expression of 5-6 CTAs represented
the patients with the highest creatinine and calcium levels, and thus
worse end-organ damage. This could possibly indicate that disease
progression could be enumerated by the number of CTAs expressed in
this panel and could be used to re-evaluate patients if disease
progression is suspected.
Figure 5: Proposed CTA cascade involved in the disease progression
of SMM. The schematic shows the most common combination of
CTAs expressed when patients were grouped according to the
number of CTAs detected, allowing for the proposal of a possible
cascade in disease progression. Different color blocks relate to the
various CTAs, as indicated on the figure.
Only a small group of patients represented either the IgA or light
chain disease subtypes, both of which are associated with a worse
overall survival [33,34]. While no significant associations could be
found regarding the IgA grouping, due to low numbers, the light chain
diseased patients all grouped together expressing 5-6 CTAs and
demonstrated advanced clinical symptoms. While this result
strengthened the association of increased CTA expression with more
aggressive/progressive disease, it unfortunately also indicated that the
light chain diseased patients could not be further risk-stratified using
this approach.
When looking at the expression of individual CTAs in the panel,
there appeared to be a definite progression or cascade-like effect, with
different CTAs being associated with more severe biochemical
parameters. MAGEA3 expression for example was highly associated
with anemia, while PAGE expression was associated with anemia and
high creatinine levels as well as stage III disease. BAGE2 expression
was only associated with stage III diseased patients and worse clinical
features, with all biochemical parameters for this grouping
representing WHO defined CRAB features [21], potentially
representing a subgroup within the stage III patients. Finally, the
expression of SSX2 and/or NYESO1 characterized a further sub
grouping within the stage III patients, representing those with light
chain disease and the patients with the greatest end-organ damage.
Our findings strongly support the hypothesis that CTA expression
plays a role in disease pathogenesis similar to previous studies that
have shown the association of co-expression and poor outcome
[18,32], thus making these genes interesting as disease targets and
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monitoring tools. We propose that the following pattern of expression
occurs during disease: MAGEC1 - PRAME - MAGEA3 - PAGE-
BAGE2 - NYESO1/SSX2. The idea of a cascade-like expression of
CTAs has been previously suggested [17,38], with their role being
linked with promoting the survival of MM cells by decreasing
transcription factors that control cell proliferation or induce apoptosis
and regulation of cell signalling and gene transcription
[17,19,20,43,44].
Other than disease stage, subtype, severity of the CRAB features and
end-organ damage indicators, other independent factors have been
previously associated with high risk patients. These include a high
PCPI [42,45], specific cytogenetic abnormalities and aneuploidy status
of the plasma cells [46]. As mentioned earlier, these results are easily
available in a clinical trial setting, however in standard health care
facilities in SA access to these specialized tests is very limited. While
standard karyotyping and FISH analysis of chromosome 13 and 14
rearrangements is being performed routinely in our institution, many
MM patient samples are unsuccessful and thus this was not included in
our current study and reflects the limited cases were this testing is of
clinical relevance. All patients analyzed for aneuploidy showed either a
normal or hyperdiploid status, which therefore did not allow us to
associate poorer non-hyperdiploid status prognostic factor with CTA
expression, but also importantly demonstrated its limited prognostic
impact in our clinical environment. While the PCPI did vary amongst
patients, we were unable to associate a specific CTA expression pattern
to the patients expressing a positive PCPI, indicating that this gene
panel cannot represent this particular independent risk factor.
In conclusion, we suggest that a molecular CTA expression panel
consisting of MAGEC1, MAGEA3, PAGE, BAGE, NYESO1 and SSX2
can be used at diagnosis as a single test to clearly group patients into
stage I and stage III disease, with further risk stratification within the
stage III patients. MAGEC1 only – stage I, MAGEC1/MAGEA3 only-
stage II, MAGEC1/MAGEA3/PAGE – stage II/early stage IIIa, BAGE
expression – more advanced stage IIIb and NYESO1/ SSX2 and BAGE
expression – advanced stage IIIc subgroup. Using the expression of
these CTAs as a guide it may then also allow clinicians to reassess
patient staging at a later stage. While treatment options are limited in
SA, being able to prognosticate patients still plays a critical role in
patient management and this molecular panel will simplify this
process. While more patients need to be analysed to strengthen our
findings, the association of MAGEC1 with all SMM patients, regardless
of disease stage, allowing easy discrimination between patients that
need immediate therapy versus AMM patients. The expression of this
antigen in all of our SMM patients also suggests that it may prove to be
a very useful marker in monitoring minimal residual disease in
patients, where previously a common genetic marker has been elusive
and we are currently investigating this possibility.
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